<p>PureTech Health PLC 赞助的 ADR（NASDAQ:PRTC - 获取免费报告）在周二的午盘交易中下跌了 0.7%。该股票最低交易价格为 16.91 美元，最后交易价格为 16.70 美元。在午盘交易中大约交易了 900 股，较日均交易量 1,977 股下降了 54%。该股票之前的收盘价为 16.81 美元。</p>
<p>获取 <strong>PureTech Health</strong> 警报：</p>
<h2>分析师评级变动</h2>
<p>另外，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 PureTech Health 股票的 &#34;卖出（d）&#34; 评级。根据 MarketBeat.com 的数据，一位研究分析师对该股票给予了卖出评级，目前该股票的共识评级为 &#34;卖出&#34;。</p>
<p><strong>阅读我们最新的 PRTC 股票分析</strong></p>
<h2>PureTech Health 下跌 0.7%</h2>
<p>该公司的 50 日移动平均价格为 17.09 美元，200 日移动平均价格为 17.60 美元。</p>
<h2>对 PureTech Health 的对冲基金看法</h2>
<p>大型投资者最近调整了对该股票的持有。Persistent Asset Partners Ltd 在第二季度购买了 PureTech Health 的新股份，价值 29,000 美元。Diadema Partners LP 在第二季度购买了 PureTech Health 的新股份，价值约 126,000 美元。Pentwater Capital Management LP 在第一季度将其在 PureTech Health 的股份增加了 39.2%。Pentwater Capital Management LP 目前拥有 33,560 股该公司的股票，价值 664,000 美元，此前在此期间又购买了 9,449 股。最后，Lansdowne Partners UK LLP 在第三季度购买了价值约 260,973,000 美元的 PureTech Health 新头寸。机构投资者持有该公司 0.04% 的股票。</p>
<h2>关于 PureTech Health</h2>
<p>（获取免费报告）</p>
<p>PureTech Health plc 从事生物技术和制药解决方案的开发和商业化，主要在美国。该公司正在开发 LYT-100，目前处于第二阶段，旨在治疗特发性肺纤维化（IPF）；以及 LYT-200，一种 IgG4 单克隆抗体，目前处于 1/2 阶段，针对 galectin-9 用于治疗实体肿瘤和血液恶性肿瘤。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 PureTech Health</li>
<li>TSX 风险投资交易所（前身为加拿大风险投资交易所）</li>
<li>为什么台湾半导体的 6.5% 下跌可能是一个明智的购买</li>
<li>投资于高市盈率成长股</li>
<li>RTX 在国防订单激增时飙升至历史新高</li>
<li>商业服务股票投资</li>
<li>聪明资金正在购买汽车供应商，而不是汽车品牌</li>
</ul>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元于 PureTech Health 吗？</h2>
<p>在你考虑 PureTech Health 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 PureTech Health 并不在名单上。</p>
<p>虽然 PureTech Health 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PRTC

<p>PureTech Health（纳斯达克代码：PRTC）的股票在周二的午盘交易中下跌了 0.7%，交易量显著减少。Weiss Ratings 重申了对该股票的 “卖出” 评级。该公司的 50 日和 200 日移动平均线分别为 17.09 美元和 17.60 美元。机构投资者最近调整了他们的持股。PureTech Health 正在开发特发性肺纤维化和实体肿瘤的治疗方案。分析师建议其他股票可能更值得购买</p>

<p>Shares of PureTech Health PLC Sponsored ADR (NASDAQ:PRTC - Get Free Report) dropped 0.7% during mid-day trading on Tuesday . The stock traded as low as $16.91 and last traded at $16.70. Approximately 900 shares were traded during mid-day trading, a decline of 54% from the average daily volume of 1,977 shares. The stock had previously closed at $16.81.</p>
<div class="lb-trans"><p>PureTech Health PLC 赞助的 ADR（NASDAQ:PRTC - 获取免费报告）在周二的午盘交易中下跌了 0.7%。该股票最低交易价格为 16.91 美元，最后交易价格为 16.70 美元。在午盘交易中大约交易了 900 股，较日均交易量 1,977 股下降了 54%。该股票之前的收盘价为 16.81 美元。</p>
</div><p>Get <strong>PureTech Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>PureTech Health</strong> 警报：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Separately, Weiss Ratings reiterated a &#34;sell (d)&#34; rating on shares of PureTech Health in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 PureTech Health 股票的 &#34;卖出（d）&#34; 评级。根据 MarketBeat.com 的数据，一位研究分析师对该股票给予了卖出评级，目前该股票的共识评级为 &#34;卖出&#34;。</p>
</div><p><strong>Read Our Latest Stock Analysis on PRTC</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 PRTC 股票分析</strong></p>
</div><h2>PureTech Health Trading Down 0.7%</h2>
<div class="lb-trans"><h2>PureTech Health 下跌 0.7%</h2>
</div><p>The firm's 50-day moving average price is $17.09 and its 200-day moving average price is $17.60.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 17.09 美元，200 日移动平均价格为 17.60 美元。</p>
</div><h2>Hedge Funds Weigh In On PureTech Health</h2>
<div class="lb-trans"><h2>对 PureTech Health 的对冲基金看法</h2>
</div><p>Large investors have recently modified their holdings of the stock. Persistent Asset Partners Ltd bought a new stake in PureTech Health in the second quarter worth $29,000. Diadema Partners LP bought a new stake in shares of PureTech Health in the 2nd quarter worth about $126,000. Pentwater Capital Management LP boosted its stake in shares of PureTech Health by 39.2% during the 1st quarter. Pentwater Capital Management LP now owns 33,560 shares of the company's stock worth $664,000 after purchasing an additional 9,449 shares during the period. Finally, Lansdowne Partners UK LLP bought a new position in PureTech Health during the 3rd quarter valued at about $260,973,000. Institutional investors own 0.04% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近调整了对该股票的持有。Persistent Asset Partners Ltd 在第二季度购买了 PureTech Health 的新股份，价值 29,000 美元。Diadema Partners LP 在第二季度购买了 PureTech Health 的新股份，价值约 126,000 美元。Pentwater Capital Management LP 在第一季度将其在 PureTech Health 的股份增加了 39.2%。Pentwater Capital Management LP 目前拥有 33,560 股该公司的股票，价值 664,000 美元，此前在此期间又购买了 9,449 股。最后，Lansdowne Partners UK LLP 在第三季度购买了价值约 260,973,000 美元的 PureTech Health 新头寸。机构投资者持有该公司 0.04% 的股票。</p>
</div><h2>About PureTech Health</h2>
<div class="lb-trans"><h2>关于 PureTech Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.</p>
<div class="lb-trans"><p>PureTech Health plc 从事生物技术和制药解决方案的开发和商业化，主要在美国。该公司正在开发 LYT-100，目前处于第二阶段，旨在治疗特发性肺纤维化（IPF）；以及 LYT-200，一种 IgG4 单克隆抗体，目前处于 1/2 阶段，针对 galectin-9 用于治疗实体肿瘤和血液恶性肿瘤。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than PureTech Health</li>
<li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li>
<li>Why Taiwan Semiconductor's 6.5% Dip Could Be a Smart Buy</li>
<li>Investing in the High PE Growth Stocks</li>
<li>RTX Surges to Record Highs as Defense Orders Explode</li>
<li>Business Services Stocks Investing</li>
<li>Smart Money Is Buying Auto Suppliers, Not Car Brands</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 PureTech Health</li>
<li>TSX 风险投资交易所（前身为加拿大风险投资交易所）</li>
<li>为什么台湾半导体的 6.5% 下跌可能是一个明智的购买</li>
<li>投资于高市盈率成长股</li>
<li>RTX 在国防订单激增时飙升至历史新高</li>
<li>商业服务股票投资</li>
<li>聪明资金正在购买汽车供应商，而不是汽车品牌</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in PureTech Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元于 PureTech Health 吗？</h2>
</div><p>Before you consider PureTech Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 PureTech Health 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 PureTech Health 并不在名单上。</p>
</div><p>While PureTech Health currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 PureTech Health 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

PureTech Health（NASDAQ:PRTC）股价下跌 0.7% - 现在是卖出的时候吗？